trial

Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects

NCTId NCT01090440
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 16 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2009-10-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2009-09-01
Primary completion
2009-10-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
GSK1144814

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

1 total
Randwick, Australia

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE1
Primary Completion Date
2009-10-09
Status
COMPLETED
relationships
The graph out of here
drug
GSK1144814
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Depressive Disorder
indication
Schizophrenia
indication